Staphylococcus aureus infections pose a significant health burden. The emergence of communityassociated methicillin-resistant S. aureus has resulted in an epidemic of skin and soft tissue infections (SSTI), and many patients experience recurrent SSTI. As S. aureus colonization is associated with subsequent infection, decolonization is recommended for patients with recurrent SSTI or in settings of ongoing transmission. S. aureus infections often cluster within households and asymptomatic carriers serve as reservoirs for transmission; therefore, a household approach to decolonization is more effective than measures performed by individuals alone. Other factors, such as environmental surface contamination, may also be considered. Novel strategies for the prevention of recurrent SSTI are needed.
INTRODUCTION
"Once the organisms gain a foothold, they may be very difficult to eradicate; sometimes boil after boil appears and these lesions may continue to develop in crops for months. The scalp, face, and shoulders are favorite sites but any part of the body may be involved; in some instances, the entire body is covered with furuncles." These prescient words, found in the chapter on skin infections from the 11 th Edition (1940) of Holt's Diseases of Infancy and Childhood [1] , are as true today of Staphylococcus aureus skin and soft tissue infections (SSTI) as they were in the pre-antibiotic era. SSTI are among the most common reasons for healthcare visits in the United States, accounting for over 14 million outpatient and emergency department visits annually [2] . Moreover, these infections frequently recur, leading to substantial morbidity in the pediatric population and provoking frustration for both patients and clinicians. In this review, we will describe the epidemiology of S. aureus SSTI, with a focus on recurrent SSTI; delineate the current paradigm of SSTI pathogenesis; and provide evidence-based recommendations for treatment and prevention of these infections.
THE EMERGENCE OF COMMUNITY-ASSOCIATED METHICILLIN-RESISTANT S. AUREUS
Staphylococcus aureus is a Gram-positive commensal bacterium that colonizes the anterior nares, as well as other anatomic sites, of approximately one third of the human population [3] [4] [5] [6] [7] . Upon leaving the site of colonization, S. aureus can infect virtually any body site, making it the most prevalent pathogen isolated from SSTIs, a leading cause of food-borne illness, the second leading cause of infectious endocarditis [8] , and an important cause (~2%) of all hospital admissions [9] . With an estimated incidence of 32 infections per 100,000 persons, S. aureus has surpassed Streptococcus pneumoniae and Haemophilus influenzae to become the most common invasive bacterial pathogen in the United States [10] .
A major challenge posed by S. aureus is antimicrobial resistance. Soon after the β-lactam antibiotics penicillin and methicillin were introduced into clinical practice, strains of antibiotic-resistant S. aureus were identified [11] . Over the next several decades, methicillin-resistant S. aureus (MRSA) became an important healthcare-associated pathogen, complicating the care of post-surgical and dialysis patients and the chronically ill [12] [13] [14] [15] . Treatment was challenging, owing to resistance to multiple antibiotics, and by the turn of the century, MRSA accounted for nearly 60% of all S. aureus isolates recovered from hospital intensive care units [16] . At present, it is projected that MRSA infections account for >100,000 hospitalizations each year in the U.S. [17] .
In the late 1990s, a shift in MRSA epidemiology occurred. After the alarming deaths of four previously healthy Midwestern children following infection with MRSA [18] , it was realized that MRSA infections were no longer restricted to those with chronic illnesses or frequent hospitalizations; rather MRSA had emerged as a community pathogen, capable of infecting healthy hosts, and thus was termed community-associated (CA) MRSA. Initially thought to represent a feral strain of healthcare-associated (HA) MRSA that had "escaped" into the community, it was soon determined that CA-MRSA strains were fundamentally different from traditional HA-MRSA strains. Compared to HA-MRSA strains, CA-MRSA strains exhibit a faster bacterial doubling time in vitro [19] , possess a smaller gene cluster (Staphylococcal Cassette Chromosome mec) conferring resistance mainly to β-lactam antibiotics (although resistance to other antimicrobials has recently emerged) [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] , and exhibit altered regulation of exotoxins and other virulence factors [37] [38] [39] [40] [41] , characteristics sports teams, though outbreaks are sporadic [71] [72] [73] [74] . In each of these high-risk groups, risk factors for infection include close contact, compromised skin integrity, and increased prevalence of colonization; in addition, outbreaks are often linked to periods of increased colonization or exposure to specific strains of S. aureus, e.g., USA300 CA-MRSA. 
PATHOGENESIS OF S. AUREUS SSTI
In the development of SSTI in an otherwise healthy individual, the site of symptomatic infection is first colonized with a relatively low number of bacteria. Staphylococci easily accomplish this, since over 80% of humans are intermittently colonized at some point with S. aureus, including 10-15% of humans who are persistently colonized [3, 75, 76] . Since colonization alone is insufficient to initiate disease, S. aureus must then reach the deeper portions of the epidermis and dermis through microabrasions of the skin, traumatic injury, or skin disruption due to inflammatory lesions (e.g., eczema). S. aureus possess a number of virulence determinants responsible for initiation and maintenance of infection [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] , representatives of which are listed in Table 1 . Upon invasion, the host inflammatory response leads to microvascular leak, production of inflammatory cytokines/chemokines, and recruitment of leukocytes (in particular, neutrophils).
drainage, is challenging in the pediatric population, often requiring sedation and postprocedural pain management. What is gained by this approach, however, is nearly immediate pain relief from large abscesses, faster wound healing and access to material for bacterial culture.
Box 2

Manifestations of skin infections
Erysipelas
Superficial skin infection characterized by well-demarcated, intensely erythematous lesions. Nearly universally due to S. pyogenes.
Cellulitis
Painful infection of the dermis and subcutaneous tissues, often occurring near breaks in the skin.
Impetigo
Relatively superficial infection leading to bullous or non-bullous lesions.
Folliculitis
Superficial or deep inflammation of the hair follicle leading to papulopustular lesions.
Furuncle
Extension of suppurative infection from the hair follicle, leading to infection of the deeper skin structures (typical abscess)
Carbuncle
An aggregate of infected follicles leading to a deep, painful mass Traditionally, drainage has been the mainstay of therapy for the majority of staphylococcal abscesses [93] ; this has held true in the contemporary era of CA-MRSA in several studies. In a prospective cohort study by Lee et al. of children presenting to a large emergency department with SSTI, >75% of children experienced clinical cure following I/D, even if prescribed an antibiotic that was ineffective (based on eventual susceptibility results) [94] . Similarly, Chen et al. determined that among children with SSTI who experienced spontaneous drainage or had I/D performed, despite MRSA being the causative agent in 69%, no differences were evident in clinical cure between those receiving cephalexin vs. clindamycin [95] . Two randomized trials, one in adults [96] and one in children [97] , have compared trimethoprim-sulfamethoxazole (TMP/SMX) to placebo after I/D of suspected staphylococcal abscesses. While both trials showed that the clinical cure rate did not differ between treatment groups, receipt of antimicrobial therapy resulted in a lower incidence of early recurrent disease. While current data are reassuring that antimicrobial agents are not required in all children, definitive data are not yet available in this population. An NIHsponsored clinical trial [98] is expected to answer this question more completely, comparing the effectiveness of clindamycin, TMP/SMX, or placebo, in conjunction with I/D, in the treatment of limited abscesses in adults and children.
Patients for whom antibiotics are currently recommended include patients at the extremes of age and those with severe or extensive disease, rapidly progressing cellulitis, abscess in an anatomic location that precludes adequate drainage, systemic illness or hemodynamic instability, associated septic phlebitis, or failure to improve after incision and drainage alone [91] . As antimicrobial resistance has increased, choices of orally effective antimicrobials have diminished. Agents with in vitro activity against MRSA are provided in Table 2 . Although antibiotic selection should be directed by one's regional antibiogram, for many communities, clindamycin and TMP/SMX remain good first line therapeutic agents for suspected CA-MRSA SSTI. However, in a large retrospective study of Tennessee children, Williams et al. found that TMP/SMX was less effective than clindamycin in both treating an initial abscess and preventing recurrences of disease [99] . Among 6407 children who underwent drainage, 9% experienced treatment failures within 14 days, and 23% had recurrence within one year; both of these outcomes were more likely in children receiving TMP/SMX, compared with clindamycin. Among 41,000 children who did not undergo a drainage procedure, TMP/SMX remained significantly less effective than clindamycin for the initial treatment of SSTI. Despite these observed differences, however, the overall success of TMP/SMX was high and, given its availability, tolerability, and low cost, TMP/SMX remains a first-line SSTI agent targeting MSSA and MRSA alike.
EPIDEMIOLOGY OF RECURRENT SSTI
As many as 70% of patients with CA-MRSA SSTI will experience recurrent SSTI over one year (Table 3) , even after successful initial treatment [59, 97, [99] [100] [101] [102] [103] [104] [105] . These recurrent infections may necessitate repeated courses of antibiotic therapy, further driving development of antibiotic resistance [106, 107] . The risk factors governing these recurrent infections are not yet clear, though there are certainly pathogen-level, host-level, and environmental-level variables that contribute to CA-MRSA transmission and risk of recurrence [108] [109] [110] . As described above, the prescription of systemic antibiotics for SSTI treatment [96, 97] , as well as the choice of antibiotic prescribed [99] , may influence the incidence of recurrent infection. This may be due to reduction of the staphylococcal colonization burden, thereby eliminating the endogenous source for infection. Indeed, several prospective studies have demonstrated eradication of MRSA carriage following treatment of SSTI with clindamycin [111, 112] .
Thus, decolonization (i.e., "the use of antimicrobial or antiseptic agents to suppress or eliminate S. aureus carriage" [91] ) is often prescribed in an attempt to prevent recurrent infections. Such therapies have traditionally been implemented in healthcare settings to prevent nosocomial S. aureus and MRSA infections [133] [134] [135] [136] [137] [138] [139] [140] [141] [142] [143] [144] . During the ongoing CA-MRSA epidemic, these measures have been extrapolated to patients in community settings [91, 145, 146] . While application of these therapies for a discrete period is effective for MRSA eradication, their effectiveness in infection prevention varies by study, and maintenance of eradication often diminishes over time [101, 103, 133-136, 141-144, 147-149] . Thus, the optimal preventive strategy for recurrent S. aureus SSTI remains elusive, and a wide variety of treatment and decolonization practices exist [91, 145, 150] .
Who should undergo decolonization?
Prior history of SSTI is a risk factor for recurrent SSTI [64, 151] . This association, coupled with the pursuit of judicious use of topical antimicrobials, suggests that decolonization is likely not necessary for patients experiencing a first SSTI. Indeed, the IDSA MRSA Clinical Practice Guidelines state that decolonization may be considered, upon optimizing wound care and hygiene (see below), for patients experiencing recurrent SSTI and for households in which there is ongoing transmission [91] .
S. aureus transmission frequently leads to infections in multiple household members; thus, when decolonization is prescribed, it should be performed by all household members. A randomized trial of 183 households conducted by Fritz et al. compared the effectiveness of decolonization of the index patient alone ("index group") to decolonization of all household members ("household group"). The 5-day decolonization regimen included hygiene education, twice daily application of 2% intranasal mupirocin, and daily body washes with 4% chlorhexidine. Three months following randomization, the incidence of SSTI was significantly lower in index patients assigned to the household decolonization group compared to those in the index group (28% vs. 47%, respectively, p=0.02). This benefit was also demonstrated for household contacts (at 3 months: 4% incidence in household group vs. 10% in index group, p=0.01) [103] .
Hygiene strategies
Before staphylococcal eradication measures are prescribed, attention to basic wound care and personal hygiene should be addressed. Education should be provided to patients and their families regarding the transmissibility of S. aureus, particularly through contact with open wounds and contaminated surfaces. Patients should be encouraged to adopt enhanced hygiene practices, including regular bathing and frequent hand washing with soap and water or alcohol-based hand sanitizers. Patients and their contacts should avoid sharing personal hygiene items (e.g., towels, deodorant, cosmetics, brushes, razors, toothbrushes, or other items that come into contact with the skin). Additional measures that may reduce transmission and infection risk include using pump or pour lotions (rather than those in jars), keeping fingernails clean and trimmed short, avoiding loofas in the bath or shower, and changing underwear, sleepwear, towels, and washcloths daily [59, 91, 101, 103, 119, 146, 152] .
Environmental surfaces serve as reservoirs for MRSA transmission and MRSA strains can persist in the environment for prolonged intervals, posing risk for the development of recurrent infections [34, 106, 109, 121-123, 128, 151, 153-156] . Thus, a barrier should be used between bare skin and surfaces touched by multiple people (e.g., exercise equipment). Additionally, patients with recurrent SSTI may consider performing environmental hygiene measures, focusing on frequently touched surfaces and using commercially available disinfectants [91, 152] . Routine laundry procedures, following the label directions on the detergent and the clothing or linens to be washed, are usually sufficient to disinfect items; use of hot water or bleach for all household laundry is not necessary [152] .
Topical antimicrobial agents
While multiple agents and technologies have been proposed or evaluated for S. aureus decolonization [157] , this review will focus on those most readily prescribed and available to patients. An important consideration of any decolonization regimen, regardless of efficacy, is the time and financial burden encumbered by patients, which heavily influences adherence and thus, the effectiveness of these measures.
Mupirocin (pseudomonic acid A) is produced naturally by Pseudomonas fluorescens [158] [159] [160] . Mupirocin targets the bacterial isoleucyl-tRNA synthetase, resulting in protein synthesis inhibition [161] . Mupirocin has antimicrobial activity against staphylococcal and streptococcal species and is prescribed for topical treatment of skin infections as well as eradication of S. aureus (both MSSA and MRSA) nasal carriage.
Retapamulin (Altabax, GlaxoSmithKline, Research Triangle Park, NC) is a semisynthetic antimicrobial derived from the natural compound pleuromutilin, produced by the edible mushroom Pleurotus mutilus [162, 163] . Retapamulin inhibits S. aureus protein synthesis by binding to the 50S ribosomal subunit [164, 165] . At present, retapamulin is approved for treatment of impetigo due to MSSA or Streptococcus pyogenes. Retapamulin has demonstrated activity against S. aureus strains exhibiting resistance to methicillin and mupirocin as well as several other systemic antibiotics [162, 163, 166] . A Phase I/IIa randomized, double-blind, placebo-controlled trial evaluated 3-and 5-day regimens of retapamulin (1%) ointment applied to the anterior nares twice daily in patients persistently colonized with S. aureus. Both retapamulin regimens demonstrated efficacy in S. aureus eradication 28 days following application, compared to placebo [167] . An ongoing randomized trial aims to determine the effectiveness of retapamulin in eradication of mupirocin-resistant MRSA from adult carriers [168] .
Chlorhexidine gluconate is a broad-spectrum biguanide cationic bactericidal agent [169, 170] . At low concentrations, chlorhexidine disrupts cytoplasmic membrane integrity; at high concentrations, it causes microbial cytoplasmic contents to congeal [169] . Multiple preparations of chlorhexidine exist, including a liquid topical antiseptic available without a prescription (Hibiclens, Mölnlycke Health Care, Norcross, GA), an oral rinse, and impregnated cloths [171] . Attractive for the purposes of decolonization, chlorhexidine provides residual antibacterial activity on the skin [148, 172] . Of note, as chlorhexidine may result in ocular and ototoxicity, patients should be instructed to avoid the eyes and ears when using this agent.
Bleach, or sodium hypochlorite, has antimicrobial activity against S. aureus both in vivo and in vitro. Dilute bleach water baths have traditionally been recommended by dermatologists to treat eczema, presumably by suppressing S. aureus growth, which is correlated with disease severity [173] [174] [175] [176] [177] . The recommended dilution of bleach varies [91, 101, 146, 173, 176] . An in vitro assay determined that the hypochlorite concentration necessary for maximal S. aureus killing was 2.5 μL of 6% hypochlorite per mL of water (equal to approximately ½ cup bleach in ¼ bathtub full of water), with an exposure time of 15 minutes yielding a >4-log decrease in S. aureus [175] . In clinical practice, to minimize skin irritation, a dilution of ¼ cup household bleach in ¼ bathtub (~13 gal) of water is recommended; for non-standard bathtubs, 1 teaspoon of bleach should be added per gallon of water. Individuals should soak in the dilute bleach water for 15 minutes. As household bleach is readily available and inexpensive, bleach baths are attractive for the purpose of decolonization. Additionally, soaking body areas that are frequently colonized with S. aureus (e.g. the groin and axillae) likely provides optimal antimicrobial effect. However, in large families, this strategy may be cumbersome and impractical. A recent feasibility study evaluated a body wash gel preparation of sodium hypochlorite (CLn BodyWash, Top MD Skin Care, Inc., Dallas, TX) in atopic dermatitis patients whose eczematous lesions yielded S. aureus [177] . Over 12 weeks, patients experienced significant improvement in severity of their atopic dermatitis; parents reported that the body wash was easier to administer than dilute bleach water baths.
Oral antibiotics for decolonization
Trials evaluating the effectiveness of systemic antibiotics in eradicating S. aureus or MRSA carriage have produced disparate results. Many of these trials have demonstrated emergence of resistant organisms with the use of oral antibiotics. Additionally, systemic antimicrobials traditionally used for decolonization, in particular rifampin, have been associated with toxicities. Thus, oral antibiotics should be reserved for patients with acute infections and are generally not recommended for staphylococcal decolonization alone [91, 143, 178] .
Effectiveness of decolonization in preventing SSTI
Several trials have evaluated decolonization measures among healthy individuals in community settings (Table 4) . S. aureus colonizes the anterior nares and the skin at multiple anatomic sites [4-7, 56-58, 179] , and a greater number of colonized sites confers increased risk of infection [59] . Additionally, the buttocks and lower extremities are frequent sites for S. aureus SSTI [49, 104, 145, 180] . Thus, a decolonization approach targeting intranasal and skin carriage has the greatest potential for success. Among recent trials, studies prescribing both intranasal mupirocin and antimicrobial body washes demonstrated significantly reduced incidence of SSTI [101, 103, 181] , while studies employing only intranasal mupirocin [147] or only antimicrobial body washes [59, 110, 180] showed no significant effect on SSTI incidence.
Many trials to date have prescribed a brief decolonization regimen (e.g., 5 days) [101, 103] ; although reduced SSTI incidence was demonstrated in the months immediately following decolonization, many participants experienced recurrent infection over longer intervals. These findings likely reflect ongoing exposure to colonized individuals and environmental reservoirs, and suggest that, especially for patients experiencing multiple infection recurrences, a periodic approach to decolonization may provide more effective, sustained protection [182] . A randomized trial of pediatric patients with SSTI by Kaplan et al. evaluated daily hygienic measures alone compared with hygienic measures accompanied by twice-weekly dilute bleach water baths performed for 3 months. Over the 12-month study period, the incidence of medically attended recurrent SSTI did not differ significantly between the group performing bleach baths compared to the hygiene-only group (17% vs. 21%, respectively, p=0.15) [59] . Of note, as not all patients with recurrent SSTI seek medical attention [7] , the effectiveness of this intervention may have been underestimated.
Based on existing evidence, guidance from the CDC and IDSA, and our clinical experience, we propose a preventive approach to recurrent staphylococcal SSTI which optimizes hygiene measures, targets nasal and skin colonization, and includes all household members (Figure 1) .
A POTENTIAL UNDESIRABLE REPERCUSSION OF DECOLONIZATION: ANTIMICROBIAL RESISTANCE
An important consideration for S. aureus decolonization is the emergence of staphylococcal strains resistant to topical antimicrobials, which has been demonstrated in vitro and in vivo (Table 5) [158-160, 170, 183-186] . This resistance in turn predicts failure of S. aureus decolonization efforts and has led to hospital outbreaks with resistant strains [159, 183, [187] [188] [189] [190] [191] [192] [193] [194] [195] . An additional concern is that the genes conferring resistance to mupirocin (most commonly mupA) and chlorhexidine (most commonly qac A/B or smr) are carried on plasmids that can also harbor genes conferring resistance to other systemic antibiotics [159, 169, 183, 188, [196] [197] [198] [199] . A challenge to U.S. clinicians is the paucity of commercially available resistance testing for mupirocin and chlorhexidine; at present there are no interpretive breakpoints established by the Food and Drug Administration [159] .
FUTURE DIRECTIONS
Despite the effectiveness of topical antimicrobials in eradicating S. aureus carriage, patients continue to suffer a high burden of subsequent SSTI over time [101, 103, 110, 147] . Thus, novel strategies are needed for the prevention of recurrent staphylococcal infections.
Vaccine
Vaccine development for S. aureus has been stymied by multiple factors, including lack of understanding of human immunity to staphylococci, redundancy of virulence determinants within the staphylococcal genome, and failure of previous vaccine candidates. The first of these failures involved a capsular polysaccharide vaccine (StaphVAX, Nabi Pharmaceuticals) given to hemodialysis patients at high risk for S. aureus disease [200] . In this study, the vaccine adequately elicited anti-capsular antibodies but failed to protect recipients from clinical disease. This vaccine has been modified significantly to include other targets and is currently in clinical development (PentaStaph, GSK). The second clinical failure occurred with a monovalent IsdB-based vaccine (V710, Merck) [201] in which vaccine recipients, who were undergoing cardiothoracic surgery, experienced greater mortality than placebo recipients. Despite these failures, staphylococcal vaccine development, as well as strategies for passive immunization [202] , continues. Once available, a suitable vaccine will be targeted to individuals at high risk for SSTI and those with recurrent infections.
Bacterial Interference and Probiotics
The endogenous microbiota (i.e., normal flora) exist in a delicate balance, vying for nutrients and adhesion sites. In this competition, commensal bacteria may interfere with the adherence and pathogenesis of potential pathogens, thereby protecting the host [203, 204] . Additionally, the endogenous microbiota may activate or augment host defenses against bacterial invaders. The concept of bacterial interference, or the use of a non-pathogenic organism to interfere with colonization and infection of a potentially pathogenic organism, is not novel. Indeed, the practice was implemented in the 1960s in an effort to abate S. aureus outbreaks among newborns due to epidemic strain type 80/81. The concept emerged from an observation that infants colonized with a non-epidemic strain type with apparent low pathogenicity, known as 502A, were at decreased risk for colonization and infection with strain type 80/81. Newborns intentionally inoculated with 502A in the nares and/or umbilicus were less likely to acquire strain type 80/81 and had a reduced incidence of infection with this epidemic strain [129, [205] [206] [207] [208] [209] [210] . It is important to note, however, that following dissemination of this practice, reports emerged of infants developing pustulosis, conjunctivitis, and other infections, including one infant who died of meningitis and septicemia, all due to the 502A strain [211] [212] [213] .
The balance of organisms within the host microbiota may play an important role in S. aureus colonization and development of symptomatic infection. In this contemporary CA-MRSA era, a U.S. military study comparing microbial communities within the anterior nares between soldiers with and without SSTI revealed a significantly higher abundance of Proteobacteria in the anterior nares of the non-SSTI group compared to soldiers with active SSTI [214] . Thus, perhaps manipulation of heterologous components of host microbiota may provide resilience against S. aureus colonization and infection. Uehara et al. conducted a trial in Japan in which persistent S. aureus nasal carriers were inoculated with a strain of Corynebacterium sp. (Co304) vs. sequential inoculation with saline and S. epidermidis. Of the 17 participants receiving Corynebacterium inoculation, S. aureus was completely eradicated in 71%. In contrast, eradication of S. aureus carriage was not demonstrated when NaCl and S. epidermidis were applied to the nares [215] . A trial conducted in Switzerland showed that consumption of a probiotic (a fermented milk drink containing Lactobacillus GG, L. acidophilus, Streptococcus thermophilus, and Bifidobacterium sp.) reduced nasal carriage of potentially pathogenic bacteria (S. aureus, Streptococcus pyogenes, β-hemolytic streptococci, and H. influenzae) compared with eating standard yogurt [216] .
SUMMARY
Ultimately, the optimal regimen for long-term S. aureus eradication and prevention of recurrent infections remains unclear. Until a more definitive prevention strategy is available, disruption of colonization, targeting multiple anatomic sites with topical antimicrobials, and effective hygiene are the cornerstones of SSTI prevention. At present, the low rate of staphylococcal resistance to commonly prescribed topical agents makes these agents highly effective in temporarily decolonizing the anterior nares and skin. Given the transmission dynamics of S. aureus within households, decolonization of all household members optimizes this approach. 
Key Points
xThe majority of children with a Staphylococcus aureus skin and soft tissue infection will experience a recurrent infection within one year.
S. aureus infections cluster within households, likely due to colonization of family members and household environmental surfaces.
A combined approach of nasal and skin decolonization is often effective in temporarily eradicating staphylococcal colonization and reducing subsequent SSTI.
A household approach to decolonization is more effective in reducing SSTI occurrence than decolonization efforts aimed at the individual patient alone. For all patients with S. aureus SSTI, we recommend optimizing hygiene measures. For those experiencing recurrent SSTI, or for households in which multiple members have experienced S. aureus infection, we recommend decolonization with a regimen that includes the application of an intranasal antibiotic (twice daily for 5 days) and daily antimicrobial body washes (performed daily for 5 days; for individuals with sensitive skin, these washes may be performed every other day for 7-10 days). These measures should be performed by all household members and may be considered for other close contacts on a case-by-case basis. Patients and their household contacts should change their bedding at the onset and again at the completion of the decolonization regimen and towels should be changed daily during the 5-day protocol. For individuals experiencing recurrent SSTI after the optimization of personal and household hygiene measures and the performance of decolonization by all household members, clinicians may consider prescribing a three-month regimen of periodic decolonization, in which an intranasal antibiotic is applied to the anterior nares twice daily for five consecutive days each month and antimicrobial body washes are performed two to three times each week. 
